<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00736489</url>
  </required_header>
  <id_info>
    <org_study_id>D0570C00007</org_study_id>
    <secondary_id>ToBe</secondary_id>
    <nct_id>NCT00736489</nct_id>
  </id_info>
  <brief_title>Single-dose Crossover Study to Investigate Pharmacodynamics of AZD3199</brief_title>
  <official_title>A Phase II, Double-blind, Placebo-controlled, Randomised, 6-way Cross-over, Single-dose Study to Investigate the Local and Systemic Effects of 3 Doses of Inhaled AZD3199 (a Î²2-agonist) Compared to Formoterol in Asthmatic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the pharmacodynamics of single doses of AZD3199
      in asthmatic patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FEV1 Peak Effect Within 0 - 24 h Post-dose</measure>
    <time_frame>0, 5min, 15min, 30min, 1h, 2h, 4h, 6h, 8h, 10h, 12h, 14h, 18h, 22h, 24h</time_frame>
    <description>Maximum FEV1 value</description>
  </primary_outcome>
  <primary_outcome>
    <measure>E22-26: the Average of the FEV1 Value Between 22 and 26 h Post Dose for Every Treatment Visit.</measure>
    <time_frame>22- 26 h post dose</time_frame>
    <description>Residual FEV1 24 h post-dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>S-potassium, Peak Effect Over 0 - 4 h Post-dose</measure>
    <time_frame>0, 15min, 30min,1h, 2h, 4h</time_frame>
    <description>Minimum S-potassium concentration (A well-known effect of beta2-agonists (AZD3199 is a beta2-agonist) is a reduction in serum potassium levels. The minimum value has therefore been evaluated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>S-potassium, Average Effect Over 0 - 4 h Post-dose</measure>
    <time_frame>0, 15min, 30min,1h, 2h, 4h</time_frame>
    <description>Average S-potassium concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FEV1 Effect at 5 Min Post-dose</measure>
    <time_frame>5min</time_frame>
    <description>FEV1 at 5 minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 Average Effect Over 0 - 24 h Post-dose</measure>
    <time_frame>0, 5min, 15min, 30min, 1h, 2h, 4h, 6h, 8h, 10h, 12h, 14h, 18h, 22h, 24h</time_frame>
    <description>FEV1 average effect over 24 h dosing interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 Average Effect Over 0 - 12 h Post-dose</measure>
    <time_frame>0, 5min, 15min, 30min, 1h, 2h, 4h, 6h, 8h, 10h, 12h</time_frame>
    <description>FEV1 average effect over 12 h day-time period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 Average Effect Over 12 - 24 h Post-dose</measure>
    <time_frame>12h, 14h, 18h, 22h, 24h</time_frame>
    <description>FEV1 average effect over 12 h night-time period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure, Peak Effect Over 0 - 4 h Post-dose</measure>
    <time_frame>0, 30min, 2h, 4h</time_frame>
    <description>Maximum SBP value over 4 h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure, Average Effect Over 0 - 4 h Post-dose</measure>
    <time_frame>0, 30min, 2h, 4h</time_frame>
    <description>Average SBP value over 4 h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure, Peak Effect Over 0 - 4 h Post-dose</measure>
    <time_frame>0, 30min, 2h, 4h</time_frame>
    <description>Minimum DBP value over 4 h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure, Average Effect Over 0 - 4 h Post-dose</measure>
    <time_frame>0, 30min, 2h, 4h</time_frame>
    <description>Average DBP value over 4 h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse, Peak Effect Over 0 - 4 h Post-dose</measure>
    <time_frame>0, 30min, 2h, 4h</time_frame>
    <description>Maximum pulse over 4 h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse, Average Effect Over 0 - 4 h Post-dose</measure>
    <time_frame>0, 30min, 2h, 4h</time_frame>
    <description>Average pulse over 4 h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate, Peak Effect Over 0 - 4 h Post-dose</measure>
    <time_frame>0, 30min, 2h, 4h</time_frame>
    <description>Maximum heart rate over 4 h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate, Average Effect Over 0 - 4 h Post-dose</measure>
    <time_frame>0, 30min, 2h, 4h</time_frame>
    <description>Average heart rate over 4 h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QTcB, Peak Effect Over 0 - 4 h Post-dose</measure>
    <time_frame>0, 30min, 2h, 4h</time_frame>
    <description>Maximum QTc Bazett over 4 h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QTcB, Average Effect Over 0 - 4 h Post-dose</measure>
    <time_frame>0, 30min, 2h, 4h</time_frame>
    <description>Average QTc Bazett over 4 h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tremor, Peak Effect Over 0 - 4 h Post-dose</measure>
    <time_frame>0, 15min, 30min, 1h, 2h, 4h</time_frame>
    <description>Maximum tremor score (4 grade scale: 0=no, 1=mild, 2=moderate or 3=severe) over 4 h.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tremor, Average Effect Over 0 - 4 h Post-dose</measure>
    <time_frame>0, 15min, 30min, 1h, 2h, 4h</time_frame>
    <description>Average tremor score (4 grade scale: 0=no, 1=mild, 2=moderate or 3=severe) over 4 h.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Palpitations, Peak Effect Over 0 - 4 h Post-dose</measure>
    <time_frame>0, 15min, 30min, 1h, 2h, 4h</time_frame>
    <description>Maximum palpitation score (4 grade scale: 0=no, 1=mild, 2=moderate or 3=severe) over 4 h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Palpitations, Average Effect Over 0 - 4 h Post-dose</measure>
    <time_frame>0, 15min, 30min, 1h, 2h, 4h</time_frame>
    <description>Average palpitation score (4 grade scale: 0=no, 1=mild, 2=moderate or 3=severe) over 4 h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma AZD3199 Cmax</measure>
    <time_frame>0, 5min, 15min, 30min, 1h, 2h, 4h, 8h, 12h, 24h</time_frame>
    <description>Maximum plasma concentration of AZD3199 measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma AZD3199 AUC0-24</measure>
    <time_frame>0, 5min, 15min, 30min, 1h, 2h, 4h, 8h, 12h, 24h</time_frame>
    <description>Area under the plasma concentration curve from time 0 to 24 h post-dose</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Asthma</condition>
  <condition>Airway Obstruction</condition>
  <arm_group>
    <arm_group_label>crossover dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD3199 120 microgram</description>
  </arm_group>
  <arm_group>
    <arm_group_label>crossover dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD3199 480 microgram</description>
  </arm_group>
  <arm_group>
    <arm_group_label>crossover dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD3199 1920 microgram</description>
  </arm_group>
  <arm_group>
    <arm_group_label>crossover dose 4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>crossover dose 5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Formoterol 9 microgram</description>
  </arm_group>
  <arm_group>
    <arm_group_label>crossover dose 6</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Formoterol 36 microgram</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD3199</intervention_name>
    <description>Dry powder for inhalation, single dose</description>
    <arm_group_label>crossover dose 1</arm_group_label>
    <arm_group_label>crossover dose 2</arm_group_label>
    <arm_group_label>crossover dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol</intervention_name>
    <description>Dry powder for inhalation, single dose</description>
    <arm_group_label>crossover dose 5</arm_group_label>
    <arm_group_label>crossover dose 6</arm_group_label>
    <other_name>Oxis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dry powder for inhalation, single dose</description>
    <arm_group_label>crossover dose 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Asthmatic patients with pre-bronchodilatory FEV1 above 60% of predicted normal and
             above 1.5 liters.

          -  Men and post-menopausal women above 18 years of age.

          -  Reversible airway obstruction in response to classical beta2-agonist (salbutamol)

          -  Non/ex-smokers

        Exclusion Criteria:

          -  Any clinically significant disease or disorder other than asthma

          -  Any clinically relevant abnormal findings at screening examinations

          -  Treatment with systemic glucocorticosteroids within the past 30 days

          -  Inhaled corticosteroid use if dosing is not kept constant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof Leif Bjermer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital in Lund, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hvidovre</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lulea</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Sweden</country>
  </location_countries>
  <removed_countries>
    <country>Finland</country>
  </removed_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&amp;studyid=238&amp;filename=CSR-D0570C00007.pdf</url>
  </link>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&amp;studyid=238&amp;filename=D0570C00007.pdf</url>
    <description>D0570C00007 CSR Synopsis</description>
  </link>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2008</study_first_submitted>
  <study_first_submitted_qc>August 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2008</study_first_posted>
  <results_first_submitted>November 30, 2010</results_first_submitted>
  <results_first_submitted_qc>February 21, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 3, 2014</results_first_posted>
  <last_update_submitted>May 8, 2014</last_update_submitted>
  <last_update_submitted_qc>May 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>airway obstruction</keyword>
  <keyword>beta2-agonist</keyword>
  <keyword>efficacy</keyword>
  <keyword>inhalation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Airway Obstruction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>AZD-3199</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study has been performed in Sweden and Denmark at two University hospital clinics and two CROs. The recruitment period was between 11 August 2008 to 22 October 2008.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>APCDEBa</title>
          <description>AZD3199 120 Mcg followed by Placebo followed by AZD3199 1920 Mcg followed by Formoterol 9 Mcg followed by Formoterol 36 Mcg followed by AZD3199 480 Mcg.</description>
        </group>
        <group group_id="P2">
          <title>BADEPCa</title>
          <description>AZD3199 480 Mcg followed by AZD3199 120 Mcg followed by Formoterol 9 Mcg followed by Formoterol 36 Mcg followed by Placebo followed by AZD3199 1920 Mcg.</description>
        </group>
        <group group_id="P3">
          <title>CBEPADa</title>
          <description>AZD3199 1920 Mcg followed by AZD3199 480 Mcg followed by Formoterol 36 Mcg followed by Placebo followed by AZD3199 120 Mcg followed by Formoterol 9 Mcg .</description>
        </group>
        <group group_id="P4">
          <title>DCPABEa</title>
          <description>Formoterol 9 Mcg followed by AZD3199 1920 Mcg followed by Placebo followed by AZD3199 120 Mcg followed by AZD3199 480 Mcg followed by Formoterol 36 Mcg.</description>
        </group>
        <group group_id="P5">
          <title>EDABCPa</title>
          <description>Formoterol 36 Mcg followed by Formoterol 9 Mcg followed by AZD3199 120 Mcg followed by AZD3199 480 Mcg followed by AZD3199 1920 Mcg followed by Placebo.</description>
        </group>
        <group group_id="P6">
          <title>PEBCDAa</title>
          <description>Placebo followed by Formoterol 36 Mcg followed by AZD3199 480 Mcg followed by AZD3199 1920 Mcg followed by Formoterol 9 Mcg followed by AZD3199 120 Mcg.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6">Cross-over study</participants>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 5</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 6</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Baseline Total</title>
          <description>Total number of patients randomized and treated in the study</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="37"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.3" lower_limit="22" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>FEV1 Peak Effect Within 0 - 24 h Post-dose</title>
        <description>Maximum FEV1 value</description>
        <time_frame>0, 5min, 15min, 30min, 1h, 2h, 4h, 6h, 8h, 10h, 12h, 14h, 18h, 22h, 24h</time_frame>
        <population>Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences. One patient on Placebo treatment had data not sufficient for computing PD parameters and for subsequent analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD3199 120 mcg</title>
            <description>AZD3199 120 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O2">
            <title>AZD3199 480 mcg</title>
            <description>AZD3199 480 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O3">
            <title>AZD3199 1920 mcg</title>
            <description>AZD3199 1920 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O4">
            <title>Formoterol 9 mcg</title>
            <description>Formoterol 9 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O5">
            <title>Formoterol 36 mcg</title>
            <description>Formoterol 36 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo inhaled via Turbuhaler</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 Peak Effect Within 0 - 24 h Post-dose</title>
          <description>Maximum FEV1 value</description>
          <population>Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences. One patient on Placebo treatment had data not sufficient for computing PD parameters and for subsequent analysis.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.56" spread="0.94"/>
                    <measurement group_id="O2" value="3.62" spread="0.94"/>
                    <measurement group_id="O3" value="3.70" spread="1.02"/>
                    <measurement group_id="O4" value="3.62" spread="1.01"/>
                    <measurement group_id="O5" value="3.69" spread="0.97"/>
                    <measurement group_id="O6" value="3.44" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>E22-26: the Average of the FEV1 Value Between 22 and 26 h Post Dose for Every Treatment Visit.</title>
        <description>Residual FEV1 24 h post-dose</description>
        <time_frame>22- 26 h post dose</time_frame>
        <population>Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences. One patient on Placebo treatment had data not sufficient for computing PD parameters and for subsequent analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD3199 120 mcg</title>
            <description>AZD3199 120 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O2">
            <title>AZD3199 480 mcg</title>
            <description>AZD3199 480 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O3">
            <title>AZD3199 1920 mcg</title>
            <description>AZD3199 1920 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O4">
            <title>Formoterol 9 mcg</title>
            <description>Formoterol 9 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O5">
            <title>Formoterol 36 mcg</title>
            <description>Formoterol 36 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo inhaled via Turbuhaler</description>
          </group>
        </group_list>
        <measure>
          <title>E22-26: the Average of the FEV1 Value Between 22 and 26 h Post Dose for Every Treatment Visit.</title>
          <description>Residual FEV1 24 h post-dose</description>
          <population>Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences. One patient on Placebo treatment had data not sufficient for computing PD parameters and for subsequent analysis.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.31" spread="0.96"/>
                    <measurement group_id="O2" value="3.35" spread="0.93"/>
                    <measurement group_id="O3" value="3.40" spread="0.94"/>
                    <measurement group_id="O4" value="3.26" spread="0.94"/>
                    <measurement group_id="O5" value="3.36" spread="0.97"/>
                    <measurement group_id="O6" value="3.23" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>S-potassium, Peak Effect Over 0 - 4 h Post-dose</title>
        <description>Minimum S-potassium concentration (A well-known effect of beta2-agonists (AZD3199 is a beta2-agonist) is a reduction in serum potassium levels. The minimum value has therefore been evaluated.</description>
        <time_frame>0, 15min, 30min,1h, 2h, 4h</time_frame>
        <population>Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences. Two patients on AZD3199 1920 mcg had data not sufficient for computing PD parameters and for subsequent analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD3199 120 mcg</title>
            <description>AZD3199 120 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O2">
            <title>AZD3199 480 mcg</title>
            <description>AZD3199 480 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O3">
            <title>AZD3199 1920 mcg</title>
            <description>AZD3199 1920 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O4">
            <title>Formoterol 9 mcg</title>
            <description>Formoterol 9 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O5">
            <title>Formoterol 36 mcg</title>
            <description>Formoterol 36 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo inhaled via Turbuhaler</description>
          </group>
        </group_list>
        <measure>
          <title>S-potassium, Peak Effect Over 0 - 4 h Post-dose</title>
          <description>Minimum S-potassium concentration (A well-known effect of beta2-agonists (AZD3199 is a beta2-agonist) is a reduction in serum potassium levels. The minimum value has therefore been evaluated.</description>
          <population>Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences. Two patients on AZD3199 1920 mcg had data not sufficient for computing PD parameters and for subsequent analysis.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.04" spread="0.19"/>
                    <measurement group_id="O2" value="4.03" spread="0.25"/>
                    <measurement group_id="O3" value="3.98" spread="0.28"/>
                    <measurement group_id="O4" value="4.04" spread="0.20"/>
                    <measurement group_id="O5" value="3.84" spread="0.21"/>
                    <measurement group_id="O6" value="4.04" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>S-potassium, Average Effect Over 0 - 4 h Post-dose</title>
        <description>Average S-potassium concentration</description>
        <time_frame>0, 15min, 30min,1h, 2h, 4h</time_frame>
        <population>Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences. Two patients on AZD3199 1920 mcg had data not sufficient for computing PD parameters and for subsequent analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD3199 120 mcg</title>
            <description>AZD3199 120 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O2">
            <title>AZD3199 480 mcg</title>
            <description>AZD3199 480 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O3">
            <title>AZD3199 1920 mcg</title>
            <description>AZD3199 1920 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O4">
            <title>Formoterol 9 mcg</title>
            <description>Formoterol 9 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O5">
            <title>Formoterol 36 mcg</title>
            <description>Formoterol 36 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo inhaled via Turbuhaler</description>
          </group>
        </group_list>
        <measure>
          <title>S-potassium, Average Effect Over 0 - 4 h Post-dose</title>
          <description>Average S-potassium concentration</description>
          <population>Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences. Two patients on AZD3199 1920 mcg had data not sufficient for computing PD parameters and for subsequent analysis.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.22" spread="0.19"/>
                    <measurement group_id="O2" value="4.21" spread="0.26"/>
                    <measurement group_id="O3" value="4.17" spread="0.26"/>
                    <measurement group_id="O4" value="4.19" spread="0.20"/>
                    <measurement group_id="O5" value="3.99" spread="0.17"/>
                    <measurement group_id="O6" value="4.21" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 Effect at 5 Min Post-dose</title>
        <description>FEV1 at 5 minutes</description>
        <time_frame>5min</time_frame>
        <population>Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences. Two patients on Placebo and 1 on AZD3199 480 mcg had data not sufficient for computing PD parameters and for subsequent analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD3199 120 mcg</title>
            <description>AZD3199 120 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O2">
            <title>AZD3199 480 mcg</title>
            <description>AZD3199 480 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O3">
            <title>AZD3199 1920 mcg</title>
            <description>AZD3199 1920 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O4">
            <title>Formoterol 9 mcg</title>
            <description>Formoterol 9 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O5">
            <title>Formoterol 36 mcg</title>
            <description>Formoterol 36 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo inhaled via Turbuhaler</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 Effect at 5 Min Post-dose</title>
          <description>FEV1 at 5 minutes</description>
          <population>Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences. Two patients on Placebo and 1 on AZD3199 480 mcg had data not sufficient for computing PD parameters and for subsequent analysis.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.36" spread="0.88"/>
                    <measurement group_id="O2" value="3.38" spread="0.92"/>
                    <measurement group_id="O3" value="3.33" spread="1.03"/>
                    <measurement group_id="O4" value="3.37" spread="0.95"/>
                    <measurement group_id="O5" value="3.47" spread="0.93"/>
                    <measurement group_id="O6" value="3.13" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 Average Effect Over 0 - 24 h Post-dose</title>
        <description>FEV1 average effect over 24 h dosing interval</description>
        <time_frame>0, 5min, 15min, 30min, 1h, 2h, 4h, 6h, 8h, 10h, 12h, 14h, 18h, 22h, 24h</time_frame>
        <population>Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences. One patient on Placebo treatment had data not sufficient for computing PD parameters and for subsequent analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD3199 120 mcg</title>
            <description>AZD3199 120 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O2">
            <title>AZD3199 480 mcg</title>
            <description>AZD3199 480 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O3">
            <title>AZD3199 1920 mcg</title>
            <description>AZD3199 1920 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O4">
            <title>Formoterol 9 mcg</title>
            <description>Formoterol 9 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O5">
            <title>Formoterol 36 mcg</title>
            <description>Formoterol 36 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo inhaled via Turbuhaler</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 Average Effect Over 0 - 24 h Post-dose</title>
          <description>FEV1 average effect over 24 h dosing interval</description>
          <population>Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences. One patient on Placebo treatment had data not sufficient for computing PD parameters and for subsequent analysis.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.31" spread="0.93"/>
                    <measurement group_id="O2" value="3.36" spread="0.91"/>
                    <measurement group_id="O3" value="3.44" spread="0.95"/>
                    <measurement group_id="O4" value="3.35" spread="0.98"/>
                    <measurement group_id="O5" value="3.46" spread="0.96"/>
                    <measurement group_id="O6" value="3.19" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 Average Effect Over 0 - 12 h Post-dose</title>
        <description>FEV1 average effect over 12 h day-time period</description>
        <time_frame>0, 5min, 15min, 30min, 1h, 2h, 4h, 6h, 8h, 10h, 12h</time_frame>
        <population>Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences. One patient on Placebo treatment had data not sufficient for computing PD parameters and for subsequent analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD3199 120 mcg</title>
            <description>AZD3199 120 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O2">
            <title>AZD3199 480 mcg</title>
            <description>AZD3199 480 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O3">
            <title>AZD3199 1920 mcg</title>
            <description>AZD3199 1920 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O4">
            <title>Formoterol 9 mcg</title>
            <description>Formoterol 9 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O5">
            <title>Formoterol 36 mcg</title>
            <description>Formoterol 36 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo inhaled via Turbuhaler</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 Average Effect Over 0 - 12 h Post-dose</title>
          <description>FEV1 average effect over 12 h day-time period</description>
          <population>Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences. One patient on Placebo treatment had data not sufficient for computing PD parameters and for subsequent analysis.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.33" spread="0.92"/>
                    <measurement group_id="O2" value="3.40" spread="0.89"/>
                    <measurement group_id="O3" value="3.48" spread="0.97"/>
                    <measurement group_id="O4" value="3.40" spread="0.98"/>
                    <measurement group_id="O5" value="3.51" spread="0.95"/>
                    <measurement group_id="O6" value="3.20" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 Average Effect Over 12 - 24 h Post-dose</title>
        <description>FEV1 average effect over 12 h night-time period</description>
        <time_frame>12h, 14h, 18h, 22h, 24h</time_frame>
        <population>Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences. One patient on Placebo treatment had data not sufficient for computing PD parameters and for subsequent analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD3199 120 mcg</title>
            <description>AZD3199 120 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O2">
            <title>AZD3199 480 mcg</title>
            <description>AZD3199 480 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O3">
            <title>AZD3199 1920 mcg</title>
            <description>AZD3199 1920 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O4">
            <title>Formoterol 9 mcg</title>
            <description>Formoterol 9 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O5">
            <title>Formoterol 36 mcg</title>
            <description>Formoterol 36 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo inhaled via Turbuhaler</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 Average Effect Over 12 - 24 h Post-dose</title>
          <description>FEV1 average effect over 12 h night-time period</description>
          <population>Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences. One patient on Placebo treatment had data not sufficient for computing PD parameters and for subsequent analysis.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.28" spread="0.95"/>
                    <measurement group_id="O2" value="3.33" spread="0.92"/>
                    <measurement group_id="O3" value="3.41" spread="0.94"/>
                    <measurement group_id="O4" value="3.30" spread="0.98"/>
                    <measurement group_id="O5" value="3.40" spread="0.98"/>
                    <measurement group_id="O6" value="3.19" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure, Peak Effect Over 0 - 4 h Post-dose</title>
        <description>Maximum SBP value over 4 h</description>
        <time_frame>0, 30min, 2h, 4h</time_frame>
        <population>Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD3199 120 mcg</title>
            <description>AZD3199 120 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O2">
            <title>AZD3199 480 mcg</title>
            <description>AZD3199 480 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O3">
            <title>AZD3199 1920 mcg</title>
            <description>AZD3199 1920 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O4">
            <title>Formoterol 9 mcg</title>
            <description>Formoterol 9 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O5">
            <title>Formoterol 36 mcg</title>
            <description>Formoterol 36 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo inhaled via Turbuhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure, Peak Effect Over 0 - 4 h Post-dose</title>
          <description>Maximum SBP value over 4 h</description>
          <population>Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126.8" spread="14.5"/>
                    <measurement group_id="O2" value="128.3" spread="13.4"/>
                    <measurement group_id="O3" value="127.4" spread="12.0"/>
                    <measurement group_id="O4" value="127.3" spread="13.2"/>
                    <measurement group_id="O5" value="129.9" spread="12.1"/>
                    <measurement group_id="O6" value="126.4" spread="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure, Average Effect Over 0 - 4 h Post-dose</title>
        <description>Average SBP value over 4 h</description>
        <time_frame>0, 30min, 2h, 4h</time_frame>
        <population>Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD3199 120 mcg</title>
            <description>AZD3199 120 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O2">
            <title>AZD3199 480 mcg</title>
            <description>AZD3199 480 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O3">
            <title>AZD3199 1920 mcg</title>
            <description>AZD3199 1920 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O4">
            <title>Formoterol 9 mcg</title>
            <description>Formoterol 9 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O5">
            <title>Formoterol 36 mcg</title>
            <description>Formoterol 36 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo inhaled via Turbuhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure, Average Effect Over 0 - 4 h Post-dose</title>
          <description>Average SBP value over 4 h</description>
          <population>Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.1" spread="13.7"/>
                    <measurement group_id="O2" value="121.8" spread="11.8"/>
                    <measurement group_id="O3" value="121.3" spread="11.9"/>
                    <measurement group_id="O4" value="120.9" spread="12.8"/>
                    <measurement group_id="O5" value="122.6" spread="11.8"/>
                    <measurement group_id="O6" value="121.3" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diastolic Blood Pressure, Peak Effect Over 0 - 4 h Post-dose</title>
        <description>Minimum DBP value over 4 h</description>
        <time_frame>0, 30min, 2h, 4h</time_frame>
        <population>Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD3199 120 mcg</title>
            <description>AZD3199 120 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O2">
            <title>AZD3199 480 mcg</title>
            <description>AZD3199 480 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O3">
            <title>AZD3199 1920 mcg</title>
            <description>AZD3199 1920 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O4">
            <title>Formoterol 9 mcg</title>
            <description>Formoterol 9 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O5">
            <title>Formoterol 36 mcg</title>
            <description>Formoterol 36 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo inhaled via Turbuhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Blood Pressure, Peak Effect Over 0 - 4 h Post-dose</title>
          <description>Minimum DBP value over 4 h</description>
          <population>Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.3" spread="10.3"/>
                    <measurement group_id="O2" value="67.6" spread="7.9"/>
                    <measurement group_id="O3" value="66.7" spread="9.6"/>
                    <measurement group_id="O4" value="66.9" spread="9.1"/>
                    <measurement group_id="O5" value="66.7" spread="9.6"/>
                    <measurement group_id="O6" value="68.8" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diastolic Blood Pressure, Average Effect Over 0 - 4 h Post-dose</title>
        <description>Average DBP value over 4 h</description>
        <time_frame>0, 30min, 2h, 4h</time_frame>
        <population>Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD3199 120 mcg</title>
            <description>AZD3199 120 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O2">
            <title>AZD3199 480 mcg</title>
            <description>AZD3199 480 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O3">
            <title>AZD3199 1920 mcg</title>
            <description>AZD3199 1920 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O4">
            <title>Formoterol 9 mcg</title>
            <description>Formoterol 9 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O5">
            <title>Formoterol 36 mcg</title>
            <description>Formoterol 36 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo inhaled via Turbuhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Blood Pressure, Average Effect Over 0 - 4 h Post-dose</title>
          <description>Average DBP value over 4 h</description>
          <population>Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.4" spread="10.0"/>
                    <measurement group_id="O2" value="72.0" spread="8.9"/>
                    <measurement group_id="O3" value="71.6" spread="9.5"/>
                    <measurement group_id="O4" value="71.5" spread="9.2"/>
                    <measurement group_id="O5" value="71.0" spread="8.6"/>
                    <measurement group_id="O6" value="72.7" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulse, Peak Effect Over 0 - 4 h Post-dose</title>
        <description>Maximum pulse over 4 h</description>
        <time_frame>0, 30min, 2h, 4h</time_frame>
        <population>Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD3199 120 mcg</title>
            <description>AZD3199 120 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O2">
            <title>AZD3199 480 mcg</title>
            <description>AZD3199 480 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O3">
            <title>AZD3199 1920 mcg</title>
            <description>AZD3199 1920 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O4">
            <title>Formoterol 9 mcg</title>
            <description>Formoterol 9 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O5">
            <title>Formoterol 36 mcg</title>
            <description>Formoterol 36 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo inhaled via Turbuhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Pulse, Peak Effect Over 0 - 4 h Post-dose</title>
          <description>Maximum pulse over 4 h</description>
          <population>Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences.</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.1" spread="9.4"/>
                    <measurement group_id="O2" value="65.0" spread="11.0"/>
                    <measurement group_id="O3" value="66.7" spread="9.9"/>
                    <measurement group_id="O4" value="63.6" spread="11.0"/>
                    <measurement group_id="O5" value="67.3" spread="11.6"/>
                    <measurement group_id="O6" value="65.3" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulse, Average Effect Over 0 - 4 h Post-dose</title>
        <description>Average pulse over 4 h</description>
        <time_frame>0, 30min, 2h, 4h</time_frame>
        <population>Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD3199 120 mcg</title>
            <description>AZD3199 120 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O2">
            <title>AZD3199 480 mcg</title>
            <description>AZD3199 480 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O3">
            <title>AZD3199 1920 mcg</title>
            <description>AZD3199 1920 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O4">
            <title>Formoterol 9 mcg</title>
            <description>Formoterol 9 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O5">
            <title>Formoterol 36 mcg</title>
            <description>Formoterol 36 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo inhaled via Turbuhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Pulse, Average Effect Over 0 - 4 h Post-dose</title>
          <description>Average pulse over 4 h</description>
          <population>Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences.</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.1" spread="8.0"/>
                    <measurement group_id="O2" value="59.0" spread="8.7"/>
                    <measurement group_id="O3" value="61.9" spread="9.1"/>
                    <measurement group_id="O4" value="58.6" spread="9.4"/>
                    <measurement group_id="O5" value="62.8" spread="10.1"/>
                    <measurement group_id="O6" value="58.8" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Rate, Peak Effect Over 0 - 4 h Post-dose</title>
        <description>Maximum heart rate over 4 h</description>
        <time_frame>0, 30min, 2h, 4h</time_frame>
        <population>Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD3199 120 mcg</title>
            <description>AZD3199 120 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O2">
            <title>AZD3199 480 mcg</title>
            <description>AZD3199 480 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O3">
            <title>AZD3199 1920 mcg</title>
            <description>AZD3199 1920 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O4">
            <title>Formoterol 9 mcg</title>
            <description>Formoterol 9 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O5">
            <title>Formoterol 36 mcg</title>
            <description>Formoterol 36 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo inhaled via Turbuhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate, Peak Effect Over 0 - 4 h Post-dose</title>
          <description>Maximum heart rate over 4 h</description>
          <population>Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences.</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.0" spread="8.8"/>
                    <measurement group_id="O2" value="64.1" spread="9.6"/>
                    <measurement group_id="O3" value="66.9" spread="9.5"/>
                    <measurement group_id="O4" value="63.8" spread="10.2"/>
                    <measurement group_id="O5" value="66.8" spread="10.9"/>
                    <measurement group_id="O6" value="64.5" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Rate, Average Effect Over 0 - 4 h Post-dose</title>
        <description>Average heart rate over 4 h</description>
        <time_frame>0, 30min, 2h, 4h</time_frame>
        <population>Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD3199 120 mcg</title>
            <description>AZD3199 120 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O2">
            <title>AZD3199 480 mcg</title>
            <description>AZD3199 480 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O3">
            <title>AZD3199 1920 mcg</title>
            <description>AZD3199 1920 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O4">
            <title>Formoterol 9 mcg</title>
            <description>Formoterol 9 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O5">
            <title>Formoterol 36 mcg</title>
            <description>Formoterol 36 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo inhaled via Turbuhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate, Average Effect Over 0 - 4 h Post-dose</title>
          <description>Average heart rate over 4 h</description>
          <population>Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences.</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.3" spread="7.9"/>
                    <measurement group_id="O2" value="59.0" spread="8.5"/>
                    <measurement group_id="O3" value="61.8" spread="9.0"/>
                    <measurement group_id="O4" value="58.6" spread="9.2"/>
                    <measurement group_id="O5" value="62.7" spread="10.0"/>
                    <measurement group_id="O6" value="58.1" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>QTcB, Peak Effect Over 0 - 4 h Post-dose</title>
        <description>Maximum QTc Bazett over 4 h</description>
        <time_frame>0, 30min, 2h, 4h</time_frame>
        <population>Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD3199 120 mcg</title>
            <description>AZD3199 120 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O2">
            <title>AZD3199 480 mcg</title>
            <description>AZD3199 480 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O3">
            <title>AZD3199 1920 mcg</title>
            <description>AZD3199 1920 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O4">
            <title>Formoterol 9 mcg</title>
            <description>Formoterol 9 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O5">
            <title>Formoterol 36 mcg</title>
            <description>Formoterol 36 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo inhaled via Turbuhaler</description>
          </group>
        </group_list>
        <measure>
          <title>QTcB, Peak Effect Over 0 - 4 h Post-dose</title>
          <description>Maximum QTc Bazett over 4 h</description>
          <population>Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences.</population>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="412" spread="21.6"/>
                    <measurement group_id="O2" value="407" spread="22.8"/>
                    <measurement group_id="O3" value="413" spread="22.0"/>
                    <measurement group_id="O4" value="408" spread="21.6"/>
                    <measurement group_id="O5" value="415" spread="24.6"/>
                    <measurement group_id="O6" value="408" spread="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>QTcB, Average Effect Over 0 - 4 h Post-dose</title>
        <description>Average QTc Bazett over 4 h</description>
        <time_frame>0, 30min, 2h, 4h</time_frame>
        <population>Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD3199 120 mcg</title>
            <description>AZD3199 120 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O2">
            <title>AZD3199 480 mcg</title>
            <description>AZD3199 480 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O3">
            <title>AZD3199 1920 mcg</title>
            <description>AZD3199 1920 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O4">
            <title>Formoterol 9 mcg</title>
            <description>Formoterol 9 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O5">
            <title>Formoterol 36 mcg</title>
            <description>Formoterol 36 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo inhaled via Turbuhaler</description>
          </group>
        </group_list>
        <measure>
          <title>QTcB, Average Effect Over 0 - 4 h Post-dose</title>
          <description>Average QTc Bazett over 4 h</description>
          <population>Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences.</population>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="398" spread="19.9"/>
                    <measurement group_id="O2" value="397" spread="22.3"/>
                    <measurement group_id="O3" value="402" spread="21.2"/>
                    <measurement group_id="O4" value="395" spread="21.4"/>
                    <measurement group_id="O5" value="406" spread="24.4"/>
                    <measurement group_id="O6" value="395" spread="19.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tremor, Peak Effect Over 0 - 4 h Post-dose</title>
        <description>Maximum tremor score (4 grade scale: 0=no, 1=mild, 2=moderate or 3=severe) over 4 h.</description>
        <time_frame>0, 15min, 30min, 1h, 2h, 4h</time_frame>
        <population>Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences. One patient on Placebo, 1 patient on formoterol 36 mcg and 1 patient on AZD3199 480 mcg had no data for subsequent analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD3199 120 mcg</title>
            <description>AZD3199 120 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O2">
            <title>AZD3199 480 mcg</title>
            <description>AZD3199 480 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O3">
            <title>AZD3199 1920 mcg</title>
            <description>AZD3199 1920 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O4">
            <title>Formoterol 9 mcg</title>
            <description>Formoterol 9 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O5">
            <title>Formoterol 36 mcg</title>
            <description>Formoterol 36 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo inhaled via Turbuhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Tremor, Peak Effect Over 0 - 4 h Post-dose</title>
          <description>Maximum tremor score (4 grade scale: 0=no, 1=mild, 2=moderate or 3=severe) over 4 h.</description>
          <population>Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences. One patient on Placebo, 1 patient on formoterol 36 mcg and 1 patient on AZD3199 480 mcg had no data for subsequent analysis.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.24"/>
                    <measurement group_id="O2" value="0.06" spread="0.24"/>
                    <measurement group_id="O3" value="0.17" spread="0.45"/>
                    <measurement group_id="O4" value="0.11" spread="0.32"/>
                    <measurement group_id="O5" value="0.47" spread="0.66"/>
                    <measurement group_id="O6" value="0.03" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tremor, Average Effect Over 0 - 4 h Post-dose</title>
        <description>Average tremor score (4 grade scale: 0=no, 1=mild, 2=moderate or 3=severe) over 4 h.</description>
        <time_frame>0, 15min, 30min, 1h, 2h, 4h</time_frame>
        <population>Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences. One patient on Placebo, 1 patient on formoterol 36 mcg and 1 patient on AZD3199 480 mcg had no data for subsequent analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD3199 120 mcg</title>
            <description>AZD3199 120 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O2">
            <title>AZD3199 480 mcg</title>
            <description>AZD3199 480 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O3">
            <title>AZD3199 1920 mcg</title>
            <description>AZD3199 1920 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O4">
            <title>Formoterol 9 mcg</title>
            <description>Formoterol 9 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O5">
            <title>Formoterol 36 mcg</title>
            <description>Formoterol 36 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo inhaled via Turbuhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Tremor, Average Effect Over 0 - 4 h Post-dose</title>
          <description>Average tremor score (4 grade scale: 0=no, 1=mild, 2=moderate or 3=severe) over 4 h.</description>
          <population>Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences. One patient on Placebo, 1 patient on formoterol 36 mcg and 1 patient on AZD3199 480 mcg had no data for subsequent analysis.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.02"/>
                    <measurement group_id="O2" value="0.02" spread="0.08"/>
                    <measurement group_id="O3" value="0.04" spread="0.11"/>
                    <measurement group_id="O4" value="0.05" spread="0.18"/>
                    <measurement group_id="O5" value="0.16" spread="0.34"/>
                    <measurement group_id="O6" value="0.01" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Palpitations, Peak Effect Over 0 - 4 h Post-dose</title>
        <description>Maximum palpitation score (4 grade scale: 0=no, 1=mild, 2=moderate or 3=severe) over 4 h</description>
        <time_frame>0, 15min, 30min, 1h, 2h, 4h</time_frame>
        <population>Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences. One patient on Placebo, 1 patient on formoterol 36 mcg and 1 patient on AZD3199 480 mcg had no data for subsequent analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD3199 120 mcg</title>
            <description>AZD3199 120 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O2">
            <title>AZD3199 480 mcg</title>
            <description>AZD3199 480 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O3">
            <title>AZD3199 1920 mcg</title>
            <description>AZD3199 1920 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O4">
            <title>Formoterol 9 mcg</title>
            <description>Formoterol 9 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O5">
            <title>Formoterol 36 mcg</title>
            <description>Formoterol 36 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo inhaled via Turbuhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Palpitations, Peak Effect Over 0 - 4 h Post-dose</title>
          <description>Maximum palpitation score (4 grade scale: 0=no, 1=mild, 2=moderate or 3=severe) over 4 h</description>
          <population>Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences. One patient on Placebo, 1 patient on formoterol 36 mcg and 1 patient on AZD3199 480 mcg had no data for subsequent analysis.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.17"/>
                    <measurement group_id="O2" value="0.03" spread="0.17"/>
                    <measurement group_id="O3" value="0.09" spread="0.37"/>
                    <measurement group_id="O4" value="0.00" spread="0.00"/>
                    <measurement group_id="O5" value="0.18" spread="0.52"/>
                    <measurement group_id="O6" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Palpitations, Average Effect Over 0 - 4 h Post-dose</title>
        <description>Average palpitation score (4 grade scale: 0=no, 1=mild, 2=moderate or 3=severe) over 4 h</description>
        <time_frame>0, 15min, 30min, 1h, 2h, 4h</time_frame>
        <population>Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences. One patient on Placebo, 1 patient on formoterol 36 mcg and 1 patient on AZD3199 480 mcg had no data for subsequent analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD3199 120 mcg</title>
            <description>AZD3199 120 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O2">
            <title>AZD3199 480 mcg</title>
            <description>AZD3199 480 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O3">
            <title>AZD3199 1920 mcg</title>
            <description>AZD3199 1920 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O4">
            <title>Formoterol 9 mcg</title>
            <description>Formoterol 9 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O5">
            <title>Formoterol 36 mcg</title>
            <description>Formoterol 36 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo inhaled via Turbuhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Palpitations, Average Effect Over 0 - 4 h Post-dose</title>
          <description>Average palpitation score (4 grade scale: 0=no, 1=mild, 2=moderate or 3=severe) over 4 h</description>
          <population>Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences. One patient on Placebo, 1 patient on formoterol 36 mcg and 1 patient on AZD3199 480 mcg had no data for subsequent analysis.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.02"/>
                    <measurement group_id="O2" value="0.01" spread="0.05"/>
                    <measurement group_id="O3" value="0.02" spread="0.08"/>
                    <measurement group_id="O4" value="0.00" spread="0.00"/>
                    <measurement group_id="O5" value="0.11" spread="0.33"/>
                    <measurement group_id="O6" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma AZD3199 Cmax</title>
        <description>Maximum plasma concentration of AZD3199 measured</description>
        <time_frame>0, 5min, 15min, 30min, 1h, 2h, 4h, 8h, 12h, 24h</time_frame>
        <population>Two patients discontinued after the first treatment period and were excluded from pharmacokinetic analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD3199 120 mcg</title>
            <description>AZD3199 120 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O2">
            <title>AZD3199 480 mcg</title>
            <description>AZD3199 480 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O3">
            <title>AZD3199 1920 mcg</title>
            <description>AZD3199 1920 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O4">
            <title>Formoterol 9 mcg</title>
            <description>Formoterol 9 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O5">
            <title>Formoterol 36 mcg</title>
            <description>Formoterol 36 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo inhaled via Turbuhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma AZD3199 Cmax</title>
          <description>Maximum plasma concentration of AZD3199 measured</description>
          <population>Two patients discontinued after the first treatment period and were excluded from pharmacokinetic analysis set.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99" lower_limit="0.21" upper_limit="2.83"/>
                    <measurement group_id="O2" value="5.39" lower_limit="1.32" upper_limit="12.4"/>
                    <measurement group_id="O3" value="24.55" lower_limit="8.99" upper_limit="44.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma AZD3199 AUC0-24</title>
        <description>Area under the plasma concentration curve from time 0 to 24 h post-dose</description>
        <time_frame>0, 5min, 15min, 30min, 1h, 2h, 4h, 8h, 12h, 24h</time_frame>
        <population>Two patients discontinued after the first treatment period and were excluded from pharmacokinetic analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD3199 120 mcg</title>
            <description>AZD3199 120 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O2">
            <title>AZD3199 480 mcg</title>
            <description>AZD3199 480 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O3">
            <title>AZD3199 1920 mcg</title>
            <description>AZD3199 1920 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O4">
            <title>Formoterol 9 mcg</title>
            <description>Formoterol 9 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O5">
            <title>Formoterol 36 mcg</title>
            <description>Formoterol 36 Mcg inhaled via Turbuhaler</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo inhaled via Turbuhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma AZD3199 AUC0-24</title>
          <description>Area under the plasma concentration curve from time 0 to 24 h post-dose</description>
          <population>Two patients discontinued after the first treatment period and were excluded from pharmacokinetic analysis set.</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.83" lower_limit="0.3" upper_limit="5.2"/>
                    <measurement group_id="O2" value="9.75" lower_limit="2.9" upper_limit="23.5"/>
                    <measurement group_id="O3" value="46.06" lower_limit="14.6" upper_limit="106.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>AZD3199 120 mcg</title>
          <description>AZD3199 120 Mcg inhaled via Turbuhaler</description>
        </group>
        <group group_id="E2">
          <title>AZD3199 480 mcg</title>
          <description>AZD3199 480 Mcg inhaled via Turbuhaler</description>
        </group>
        <group group_id="E3">
          <title>AZD3199 1920 mcg</title>
          <description>AZD3199 1920 Mcg inhaled via Turbuhaler</description>
        </group>
        <group group_id="E4">
          <title>Formoterol 9 mcg</title>
          <description>Formoterol 9 Mcg inhaled via Turbuhaler</description>
        </group>
        <group group_id="E5">
          <title>Formoterol 36 mcg</title>
          <description>Formoterol 36 Mcg inhaled via Turbuhaler</description>
        </group>
        <group group_id="E6">
          <title>Placebo</title>
          <description>Placebo inhaled via Turbuhaler</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Prior to any publication or disclosure, the PI provides AstraZeneca with preliminary data and drafts and with the proposed final manuscript. AstraZeneca shall have a period of 30 days from receipt of the proposed final manuscript to review it and may within such time frame require that submission for publication or disclosure be delayed.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Carin Jorup, MSD</name_or_title>
      <organization>AstraZeneca</organization>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

